This study aims to evaluate the efficacy of genotype-informed Bayesian dosing of tacrolimus in optimising drug exposure among paediatric solid organ transplant recipients. By tailoring tacrolimus dosage based on individual genetic makeup and using Bayesian modeling to predict drug levels, the researchers hope to increase the likelihood of achieving therapeutic drug concentrations while minimising the risk of adverse events associated with subtherapeutic or supratherapeutic exposure.
Age 1-18 years of age
Kidney, liver or heart transplant recipients
Participant and/or parent consent to the study (prospective arm only)
Previous liver transplant.
Lung OR Intestinal transplant.
Insufficient time before transplant for pharmacogenomic analysis (prospective arm only)
Immunosuppressant regimen not containing tacrolimus immediate release product